Clinical trials: AMD
Hippel-Lindau Disease
EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
This study will test the ability of the experimental drug EYE001 to reduce retinal thickening and improve vision in patients with Von Hippel-Lindau syndrome (VHL).
- Trial name
- NCT00056199
- Testing
- EYE001
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Eye Institute (NEI)
Age-Related Macular Degeneration
Deciphering AMD by Deep Phenotyping and Machine Learning- Prospective Study - SUMMIT (Part 2)
We will conduct a prospective, non-interventional roll-over extension of the PINNACLE study (Deciphering AMD by deep phenotyping and machine learning).
- Trial name
- NCT06682455
- Where
- 8 sites in Austria, United Kingdom
- Volunteers
- 300 people
- Sponsor
- University of Southampton
Diabetic Retinopathy, Glaucoma
AI for the Detection of Retinal Disease and Glaucoma in Patients With Diabetes Mellitus in Primary Care
Background: Diabetic retinopathy (DR) is one of the most important causes of blindness worldwide, especially in developed countries.
- Conditions
- Diabetic Retinopathy, Glaucoma, Age-Related Macular Degeneration, Choroidal Nevus
- Trial name
- NCT04132401
- Testing
- algorithm
- Where
- Spain
- Volunteers
- 902 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Enzyme Replacement Therapy in Pompe Disease
Cardiopulmonary Exercise Test to Quantify Enzyme Replacement Response in Pediatric Pompe Disease
Introduction: Enzyme replacement therapy (ERT) with Myozyme improved the prospect of Pompe disease patients. Our aim was to evaluate ERT acute effect on exercise capacity in pediatric Pompe patients.
- Trial name
- NCT03147664
- Volunteers
- 5 people
- Sponsor
- Rambam Health Care Campus
Diabetic Retinopathy (DR), Retinal Vein Occlusion (RVO)
High-throughput Large-model-based AI-assisted Diagnosis Using OCT
This observational study aims to establish key technologies for high-throughput, large-model-based AI-assisted diagnosis using optical coherence tomography (OCT) and OCT angiography (OCTA).
- Conditions
- Diabetic Retinopathy (DR), Retinal Vein Occlusion (RVO), Age-Related Macular Degeneration (AMD), Pathologic Myopia
- Trial name
- NCT07249307
- Testing
- No intervention
- Volunteers
- 2,000 people
- Sponsor
- Peking Union Medical College Hospital
Geographic Atrophy
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
This multicenter open-label extension study is designed to evaluate the safety and tolerability of lampalizumab intravitreal injections in participants with GA secondary to age-related macular degeneration (AMD) who completed 96…
- Trial name
- NCT02745119
- Testing
- Lampalizumab
- Where
- 208 sites in United States, Australia and 17 more
- Volunteers
- 994 people
- Sponsor
- Hoffmann-La Roche
Uveitis, Cystoid Macular Edema
The Comparison Between the Therapeutic Affect of Intravitreal Diclophenac and Triamcinolone in Persistent Uveitic Cystoids Macular Edema
Cystoids macular edema (CME) is one of the most common causes of low vision due to uveitis. The treatment for reducing the intra-ocular inflammation can decrease the macular edema.
- Trial name
- NCT00893854
- Testing
- Diclophenac, Triamcinolone
- Where
- Iran
- Sponsor
- Shahid Beheshti University of Medical Sciences
Pompe's Disease
Pompe Prevalence Study in Patients With Muscle Weakness Without Diagnosis
An international consensual group recommends confirming the diagnosis of the Pompe disease after a dried blood spot (DBS) with a dosage of the enzymatic activity in other tissue.
- Trial name
- POPS (NCT00830583)
- Testing
- blood test
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Retinal Degeneration, Genetic Disease
Saffron Supplementation in Stargardt's Disease
The general area of research in which this project has been designed is that of retinal degeneration related to mutations in the ABCR gene, responsible of Stargardt disease/fundus flavimaculatus retinal dystrophy (STD/FF).
- Conditions
- Retinal Degeneration, Genetic Disease, Single-Gene Defects, Macular Dystrophy
- Trial name
- STARSAF02 (NCT01278277)
- Testing
- Saffron supplementation
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Catholic University of the Sacred Heart
Diabetic Retinopathy, Age Related Macular Degeneration
Retinal Care Data Repository
The Retinal Care Data Repository's primary objective is to make data available for Retinal Care to develop algorithms that improve the care of people with retinal diseases.
- Trial name
- NCT04794907
- Testing
- Observation
- Volunteers
- 1,000 people
- Sponsor
- Retinal Care Inc.
Diabetic Retinopathy, Age-Related Macular Degeneration (AMD)
Genetics and Markers of Degenerative and Inflammatory Eye Diseases
This study will identify genes that are associated with inflammation or degeneration of the retina (membrane lining the back of the eye that relays vision signals to the brain).
- Conditions
- Diabetic Retinopathy, Age-Related Macular Degeneration (AMD), Uveitis
- Trial name
- NCT00647439
- Where
- United States
- Volunteers
- 609 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Ophthalmic Diseases (Specific Types Not Restricted), Cataract
Research on a New Intelligent Mobile Screening and Diagnosis Pattern for Ocular Diseases
The global distribution of primary ophthalmic medical resources is uneven, and the traditional eye disease screening model has problems such as low efficiency, high cost and limited coverage.
- Conditions
- Ophthalmic Diseases (Specific Types Not Restricted), Cataract, Refraction Error, Diabetic Retinopathy (DR)
- Trial name
- NCT07003165
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Age-related Macular Degeneration
Visual Remapping to Aid Reading With Field Loss
Reading performance in patients with Central Vision Loss and age matched controls with artificial scotomas will be measured with and without different kinds of remapping of missing text to different parts of the visual field.
- Trial name
- NCT03848663
- Testing
- Traditional Remapping, Personalized Remapping
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Stargardt Disease, Stargardt Macular Dystrophy
A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions
Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye.
- Conditions
- Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
- Trial name
- DEVOTE (NCT07734064)
- Testing
- ASP2020
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Astellas Institute for Regenerative Medicine
Macular Degeneration
Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy
This study will determine whether the drug celecoxib (Celebrex® (Registered Trademark)) can help stabilize or improve vision in patients with age-related macular degeneration (AMD) who are receiving photodynamic therapy, or PDT…
- Trial name
- NCT00043680
- Testing
- Celecoxib
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Eye Institute (NEI)
Glycogen Storage Disease Type II
A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-onset Pompe Disease
Pompe disease (also known as glycogen storage disease type II, "GSD-II") is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA).
- Trial name
- NCT00059280
- Testing
- Myozyme
- Where
- 8 sites in United States, France and 3 more
- Volunteers
- 16 people
- Sponsor
- Genzyme, a Sanofi Company
Pompe's Disease
Feasability and Interest of Screening for Infantile Pompe's Diseases at Birth
Given the 100 fold increase of the incidence of Pompe's disease in Western French Guiana, the objective of the present study is to implement systematic screening in newborns in French Guiana in order to start treatment before the…
- Trial name
- DEPIPOMP1 (NCT02904395)
- Testing
- observational (no intervention)
- Volunteers
- 3,413 people
- Sponsor
- Centre Hospitalier de Cayenne
Cardiac Diseases, Muscular Weakness
Biomarker for Pompe Disease (BioPompe)
Development of a new MS-based biomarker for the early and sensitive diagnosis of Pompe disease from blood (plasma)
- Conditions
- Cardiac Diseases, Muscular Weakness, Hepato-splenomegaly, Lung Disease
- Trial name
- BioPompe (NCT01457443)
- Where
- 4 sites in Germany, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Neovascularization, Macular Degeneration
Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection
Background/aims: Aflibercept is an approved therapy for neovascular macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion and other retinal conditions.
- Conditions
- Neovascularization, Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion
- Trial name
- Zaltrap (NCT02486484)
- Testing
- ziv-aflibercept
- Where
- Lebanon
- Volunteers
- 100 people
- Sponsor
- Rafic Hariri University Hospital
Glycogen Storage Disease Type II
A Prospective, Observational Study in Patients With Late-Onset Pompe Disease
Pompe disease (also known as glycogen storage disease type II, "GSD-II") is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA).
- Trial name
- NCT00077662
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 61 people
- Sponsor
- Genzyme, a Sanofi Company